{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:57Z","timestamp":1793744217882,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41375-019-0517-6","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T09:07:35Z","timestamp":1563959255000},"page":"2127-2143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"33","author":[{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim S.","family":"Iskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"517_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221\u20137.","journal-title":"JAMA Oncol"},{"key":"517_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346.","journal-title":"Lancet Oncol"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17:5311\u201321.","journal-title":"Clin Cancer Res"},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bjh.13780","volume":"171","author":"DS Das","year":"2015","unstructured":"Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D, et al. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015;171:798\u2013812.","journal-title":"Br J Haematol"},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525\u201330.","journal-title":"Blood"},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281:365\u201382.","journal-title":"J Intern Med"},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734\u201343.","journal-title":"Clin Cancer Res"},{"key":"517_CR9","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281\u201390.","journal-title":"Blood"},{"key":"517_CR10","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907\u201316.","journal-title":"Blood"},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"16639","DOI":"10.1074\/jbc.M200360200","volume":"277","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639\u201347.","journal-title":"J Biol Chem"},{"key":"517_CR12","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V120.21.4008.4008","volume":"120","author":"Y Chen","year":"2012","unstructured":"Chen Y, Usmani SZ, Hu B, Papanikolau X, Heuck C, Epstein J,\u00a0et al. Carfilzomib induces differentiation of mesenchymal stromal cells toward osteoblast via activation of \u03b2-catenin\/TCF signaling. Blood. 2012;120:4008\u20134008.","journal-title":"Blood"},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/leu.2012.183","volume":"27","author":"MA Hurchla","year":"2013","unstructured":"Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27:430\u201340.","journal-title":"Leukemia"},{"key":"517_CR14","first-page":"1826","volume":"130","author":"A Suvannasankha","year":"2017","unstructured":"Suvannasankha A, Abonour R, Farag S, Silbermann RW, Wongsaengsak S, Cangany MH, et al. Phase 2 study of carfilzomib and bone metabolism in patients with relapsed multiple myeloma. Blood. 2017;130:1826.","journal-title":"Blood"},{"key":"517_CR15","unstructured":"Kashiwazaki S, Kobori M, Matsushita M, Hattori Y. Immunogenic cell death against multiple myeloma. Presented at the 15th Annual Meeting of Japan Research Association for Immunotherapeutics in Tokyo. 2018."},{"key":"517_CR16","doi-asserted-by":"crossref","first-page":"26982","DOI":"10.18632\/oncotarget.4831","volume":"6","author":"G Yang","year":"2015","unstructured":"Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, et al. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015;6:26982\u201394.","journal-title":"Oncotarget"},{"key":"517_CR17","first-page":"303","volume":"41","author":"G Perel","year":"2016","unstructured":"Perel G, Bliss J, Thomas CM. Carfilzomib (Kyprolis): a novel proteasome inhibitor for relapsed and\/or refractory multiple myeloma. P T. 2016;41:303\u20137.","journal-title":"P T"},{"key":"517_CR18","first-page":"3125","volume":"130","author":"H Ludwig","year":"2017","unstructured":"Ludwig H, Spencer A, Kovacsovics T, Gabrail NY, Minuk L, Kimball AS, et al. Comparison of proteasome inhibition activity between carfilzomib and bortezomib in the phase 3 endeavor study. Blood 2017;130:3125.","journal-title":"Blood"},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327\u201337.","journal-title":"Lancet Oncol"},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"517_CR21","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood.V128.22.3309.3309","volume":"128","author":"H Ludwig","year":"2016","unstructured":"Ludwig H, Moreau P, Dimopoulos MA, Mateos M-V, Kaiser MF, Feng S, et al. Health related quality of life results from the open-label, randomized, phase III Endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2016;128:3309.","journal-title":"Blood"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728\u201334.","journal-title":"J Clin Oncol"},{"key":"517_CR23","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart AK, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, H\u00e1jek R, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34:3921\u201330.","journal-title":"J Clin Oncol"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"517_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953\u201364.","journal-title":"Lancet Oncol"},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1016\/j.clml.2018.07.130","volume":"18","author":"P Moreau","year":"2018","unstructured":"Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, et al. Patient-reported outcomes (PROs) from the phase 3 A.R.R.O.W. Study comparing once-weekly versus twice-weekly carfilzomib dosing in relapsed and refractory multiple myeloma (RRMM). Clin Lymphoma, Myeloma Leuk. 2018;18:S240.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801\u20139.","journal-title":"Blood"},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.3324\/haematol.2014.110395","volume":"99","author":"D Dytfeld","year":"2014","unstructured":"Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99:e162\u2013e164.","journal-title":"Haematologica"},{"key":"517_CR29","unstructured":"Jakubowiak A, Raje N, Vij R, Reece D, Berdeja J, Vesole D, et al. Improved efficacy after incorporating autologous stem cell transplant (ASCT) into KRd treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) in newly diagnosed multiple myeloma. Haematologica. 2016;101(s1):Abstract S101."},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746\u201354.","journal-title":"JAMA Oncol"},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41409-018-0170-0","volume":"53","author":"N Tageja","year":"2018","unstructured":"Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, et al. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. Bone Marrow Transpl. 2018;53:1445\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","volume":"4","author":"D Kazandjian","year":"2018","unstructured":"Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, et al. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial. JAMA Oncol. 2018;4:1781\u20133.","journal-title":"JAMA Oncol"},{"key":"517_CR33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V128.22.675.675","volume":"128","author":"T Zimmerman","year":"2016","unstructured":"Zimmerman T, Raje NS, Vij R, Reece D, Berdeja JG, Stephens LA, et al. Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Blood. 2016;128:675.","journal-title":"Blood"},{"key":"517_CR34","first-page":"4533","volume":"130","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak AJ, Raje N, Vij R, Reece D, Berdeja JG, Stephens L, et al. High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial. Blood. 2017;130:4533.","journal-title":"Blood"},{"key":"517_CR35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood.V128.22.1142.1142","volume":"128","author":"M Roussel","year":"2016","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Belhadj K, Facon T, Garderet L, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the Intergroupe Francophone Du My\u00e9Lome (IFM) Krd phase II study. Blood. 2016;128:1142. Presented at the ASH 2016 Annual Meeting, San Diego, CA; December 3\u20136, 2016","journal-title":"Blood"},{"key":"517_CR36","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood-2018-99-117120","volume":"132","author":"N Korde","year":"2018","unstructured":"Korde N, Mastey D, Mailankody S, Hassoun H, Lesokhin AM, Smith EL, et al. MRD-response driven phase I\/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg\/m2) in combination with lenalidomide and dexamethasone. Blood. 2018;132:1983.","journal-title":"Blood"},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","volume":"124","author":"S Bringhen","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124:63\u201369.","journal-title":"Blood"},{"key":"517_CR38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","volume":"132","author":"F Gay","year":"2018","unstructured":"Gay F, Cerrato C, Rota Scalabrini D, Galli M, Belotti A, Zamagni E, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized Forte trial in newly diagnosed multiple myeloma (NDMM). Blood. 2018;132:121. Presented at the ASH 2018 Annual Meeting, San Diego, CA; December 1\u20134, 2018.","journal-title":"Blood"},{"key":"517_CR39","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood-2018-99-112656","volume":"132","author":"M-V Mateos","year":"2018","unstructured":"Mateos M-V, Mart\u00ednez-L\u00f3pez J, Rodriguez Otero P, Ocio EM, Gonzalez MS, Oriol A, et al. Curativestategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, Lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood. 2018;132:2142.","journal-title":"Blood"},{"key":"517_CR40","first-page":"4541","volume":"130","author":"FM Gay","year":"2017","unstructured":"Gay FM, Rota Scalabrini D, Belotti A, Galli M, Zamagni E, Offidani M, et al. A randomized study of carfilzomib-lenalidomide-dexamethasone vs carfilzomib-cyclophosphamide-dexamethasone induction in newly diagnosed myeloma patients eligible for transplant: high efficacy in high- and standard-risk patients. Blood. 2017;130:4541.","journal-title":"Blood"},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","volume":"125","author":"P Sonneveld","year":"2015","unstructured":"Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, et al. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2015;125:449\u201356.","journal-title":"Blood"},{"key":"517_CR42","first-page":"3141","volume":"130","author":"R Wester","year":"2017","unstructured":"Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, et al. Carfilzomib combined with thalidomide and low-dose dexamethasone for remission induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma: the Carthadex trial. Blood. 2017;130:3141.","journal-title":"Blood"},{"issue":"S1","key":"517_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000060","volume":"2","author":"R Wester","year":"2018","unstructured":"Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, et al. Update of the phase 2 study of carfilzomib thalidomide and low-dose dexamethasone as induction\/consolidation in newly diagnosed transplant eligible patients with multiple myeloma, Carthadex trial. HemaSphere. 2018;2(S1):1\u20131113.","journal-title":"HemaSphere."},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjh.13296","volume":"169","author":"JR Mikhael","year":"2015","unstructured":"Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, et al. Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015;169:219\u201327.","journal-title":"Br J Haematol"},{"key":"517_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40164-018-0110-0","volume":"7","author":"H Gregersen","year":"2018","unstructured":"Gregersen H, Do T, Kristensen IB, Fr\u00f8lund UC, Andersen NF, Nielsen LK, et al. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Exp Hematol Oncol. 2018;7:18.","journal-title":"Exp Hematol Oncol"},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","volume":"42","author":"S Moriya","year":"2013","unstructured":"Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol. 2013;42:1541\u201350.","journal-title":"Int J Oncol"},{"key":"517_CR47","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/blood.V128.22.4518.4518","volume":"128","author":"PA Forsberg","year":"2016","unstructured":"Forsberg PA, Rossi AC, Pearse RN, Perry A, Pekle K, Jayabalan D, et al. Carfilzomib induction with lenalidomide and clarithromycin consolidation and lenalidomide maintenance (CarBiRD) for multiple myeloma (MM). Blood. 2016;128:4518.","journal-title":"Blood"},{"key":"517_CR48","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns D, Striha A, Hockaday A, et al. A quadruplet regimen comprising carfilzomib, cyclophosphamide, lenalidomide, dexamethasone (KCRD) vs an immunomodulatory agent containing triplet (CTD\/CRD) induction therapy prior to autologous stem cell transplant: results of the Myeloma XI study. Blood. 2018;132:302. Presented at the ASH 2018 Annual Meeting, San Diego, CA; December 1\u20134, 2018."},{"key":"517_CR49","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Usmani SZ, Krishnan A, Krishnan A, Lonial S, Comenzo R, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study. Blood. 2017;130:3110.","journal-title":"Blood"},{"issue":"15_suppl)","key":"517_CR50","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/JCO.2017.35.15_suppl.8000","volume":"35","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak AJ, Chari A, Lonial S, Weiss BM, Comenzo RL, Wu K, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol. 2017;35(15_suppl)):8000\u20138000.","journal-title":"J Clin Oncol"},{"key":"517_CR51","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2018-99-114311","volume":"132","author":"O Landgren","year":"2018","unstructured":"Landgren O, Thoren K, Hultcrantz M, et al. Bone marrow-based and longitudinal blood-based MRD tracking in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd): a correlative and clinical phase II study. Blood. 2018;132:3281.","journal-title":"Blood"},{"key":"517_CR52","unstructured":"Genmab announces positive topline results in phase III CASSIOPEIA study of daratumumab in front line multiple myeloma. Genmab. October 21, 2018. https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-positive-topline-results-phase-iii-cassiopeia . Accessed May 3, 2019."},{"key":"517_CR53","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","volume":"18","author":"DC Ziogas","year":"2017","unstructured":"Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA. An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharm. 2017;18:1883\u201397.","journal-title":"Expert Opin Pharm"},{"key":"517_CR54","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753\u201361.","journal-title":"Haematologica"},{"key":"517_CR55","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","volume":"2","author":"A Chari","year":"2018","unstructured":"Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials. Blood Adv. 2018;2:1633\u201344.","journal-title":"Blood Adv"},{"key":"517_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/10245332.2017.1328165","volume":"22","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology 2017;22:585\u201391.","journal-title":"Hematology"},{"key":"517_CR57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clml.2016.01.008","volume":"16","author":"J Mikhael","year":"2016","unstructured":"Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016;16:241\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"517_CR58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","volume":"11","author":"M Delforge","year":"2010","unstructured":"Delforge M, Blad\u00e9 J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11:1086\u201395.","journal-title":"Lancet Oncol"},{"key":"517_CR59","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1080\/10428194.2017.1403020","volume":"59","author":"N Lendvai","year":"2018","unstructured":"Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, et al. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leuk Lymphoma. 2018;59:1981\u20135.","journal-title":"Leuk Lymphoma"},{"key":"517_CR60","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12:286\u201395.","journal-title":"Nat Rev Clin Oncol"},{"key":"517_CR61","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood-2018-99-112289","volume":"132","author":"O Landgren","year":"2018","unstructured":"Landgren O, Siegel DS, Auclair D, Chari A, Boedigheimer M, Welliver T, et al. Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: results from the prospective, longitudinal, observational Commpass study. Blood. 2018;132:799.","journal-title":"Blood"},{"key":"517_CR62","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood-2018-99-115017","volume":"132","author":"B Li","year":"2018","unstructured":"Li B, Ren K, Shen L, Hou P, Su Z, Di Bacco A, et al. Comparing bortezomib-lenalidomide-dexamethasone (VRd) with carfilzomib-lenalidomide-dexamethasone (KRd) in the patients with newly diagnosed multiple myeloma (NDMM) in two observational studies. Blood. 2018;132:3298.","journal-title":"Blood"},{"key":"517_CR63","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519.","journal-title":"JAMA Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0517-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T09:53:58Z","timestamp":1695030838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0517-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0517-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Landgren has received research funding from the National Institutes of Health, U.S. Food and Drug Administration, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm; has served on honoraria\/advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees for clinical trials led by Takeda, Merck, Janssen. Dr Sonneveld received research funding from Janssen, Celgene, Amgen, Karyopharm, SkylineDx, Takeda, and Novartis; and received personal fees from Janssen, Celgene, and Amgen. Dr Jakubowiak repots consultancy, honoraria, and membership on an entity\u2019s Board of Directors or Advisory Committees fees from Amgen, ABBVIE, BMS, Celgene, Janssen, Karyopharm, Millennium, Takeda, Sanofi, and SkylineDx. Dr Mohty has no disclosures to report. Dr Iskander and Dr Mezzi are employees of and own stock in Amgen, Inc. Dr Siegel reports honoraria and consulting or advisory role fees for Celgene, Amgen, Merck, Janssen, BMS, Takeda, and Karyopharm; speakers\u2019 bureau participation for Celgene, Amgen, Merck, Janssen, BMS, and Takeda; and research funding from Celgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}